Pentixapharm的新放射性药剂展示了诊断与激素有关的高血压和治疗膀胱癌的希望。 Pentixapharm's new radiopharmaceutical shows promise for diagnosing hormone-related hypertension and treating bladder cancer.

在EANM 2025年大会上,设在柏林的Pentixapharm介绍了其CXCR4目标放射药物平台的新数据,表明[68Ga]Ga-Pentixafor可能改进初级阿尔多斯特氏症的诊断和分型,这是二级高血压的一个常见原因,有可能为肾上腺素取样提供一种较少侵入性的替代方法。 At the EANM 2025 congress, Berlin-based Pentixapharm presented new data on its CXCR4-targeting radiopharmaceutical platform, showing that [⁶⁸Ga]Ga-PentixaFor may improve diagnosis and subtyping of Primary Aldosteronism, a common cause of secondary hypertension, potentially offering a less invasive alternative to adrenal venous sampling. 膀胱癌[177Lu]Lu-PentixaTher在膀胱癌中的早期人类先期结果显示了治疗活动,支持将CXCR4作为肿瘤学的一个可行目标。 Early first-in-human results for [¹⁷⁷Lu]Lu-PentixaTher in bladder cancer indicated therapeutic activity, supporting CXCR4 as a viable target in oncology. 该平台的潜力涵盖多种疾病,PAA的准备就绪诊断候选阶段为第三阶段,若干治疗方案正在开发中。 The platform’s potential spans multiple diseases, with a Phase 3-ready diagnostic candidate for PA and several therapeutic programs in development.